Notably, several senolytic compounds aiming to restore apoptotic mechanisms via BCL-2, BCL-XL, and BCL-W inhibition in cancer cells are currently undergoing clinical trials, highlighting their potential as adjuvants in cancer management [156]. Here, BCL2 is linked to cancer.